<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561327</url>
  </required_header>
  <id_info>
    <org_study_id>P2132V1</org_study_id>
    <nct_id>NCT00561327</nct_id>
  </id_info>
  <brief_title>PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MSD SHARP and DOHME GMBH Haar Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether losartan metabolites are effective in
      inducing PPARγ target genes in monocytes in losartan-treated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The losartan metabolite EXP3179 potently induces the activity of the peroxisome
      proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear
      hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ
      ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular
      morbidity and mortality in diabetic patients.

      Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites
      in patients would markedly improve the pharmacological profile of losartan by combining
      anti-hypertensive and highly beneficial metabolic actions. We developed the following
      hypothesis:

        1. Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels
           of EXP3179 to activate PPARγ.

        2. PPARγ target genes are induced in monocytes from losartan-treated patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Patients chronically treated with drug losartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Patients not chronically treated with losartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 19-80

          -  Sex: male or female

          -  Prior diagnosis of treated hypertension

          -  Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case);

          -  or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/
             control).

        Exclusion Criteria:

          -  Non-steroidal anti-inflammatory drugs (exception: Acetyl salicylic acid) for the past
             21 days (due to structural homologies to glitazones, and activating effects on PPARγ)

          -  Therapy with glitazones for the past 21 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eckart Fleck, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Kintscher, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Pharmacology Charite University Medicine Berlin Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eckart Fleck, Prof</last_name>
    <phone>+49-30-4593-2400</phone>
    <email>fleck@dhzb.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Philipp Stawowy, Dr</last_name>
    <phone>+49-30-4593-2473</phone>
    <email>stawowy@dhzb.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>German Heart Institute</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckart Fleck, Prof</last_name>
      <phone>+49-30-4593 2400</phone>
      <email>fleck@dhzb.de</email>
    </contact>
    <contact_backup>
      <last_name>Philipp Stawowy, Dr</last_name>
      <phone>+49-30-45932473</phone>
      <email>stawowy@dhzb.de</email>
    </contact_backup>
    <investigator>
      <last_name>Eckart Fleck, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2007</study_first_submitted>
  <study_first_submitted_qc>November 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>November 16, 2007</last_update_submitted>
  <last_update_submitted_qc>November 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2007</last_update_posted>
  <keyword>hypertension</keyword>
  <keyword>angiotensin receptor blockers</keyword>
  <keyword>peroxisome proliferator activated receptor gamma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

